Filing Flows › 8-K events › Acumen Pharmaceuticals
Acumen Pharmaceuticals: termination of a material definitive agreement
Form 8-K filed Nov 5, 2026 · items 1.02
What the filing says
As previously disclosed in its Current Report on Form 8-K filed on November 10, 2023, Acumen Pharmaceuticals, Inc. (the “Company”) entered into a Loan and Security Agreement, dated November 10, 2023 (the “Loan Agreement”), with K2 HealthVentures LLC (the “Lender”). The Loan Agreement provided for a term loan facility (
Read the filing on SEC EDGAR →
What usually followsAcross 2,368 8-Ks reporting Item 1.02 (termination of a material agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.5%, up 51% of the time); over the following 21 sessions, +1.1%. Every item ranked →
What this kind of filing means
Item 1.02 — Termination of a material definitive agreement. Ending a material agreement can remove revenue, financing or a planned deal; the filing says who ended it and whether penalties apply.
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.